John Gerardi asks the tough questions about the Trump administration's slow action on restricting the abortion pill, including the FDA's approval of a new generic version. With Jonathan Keller, he explores the legal, political, and moral stakes of Mifepristone regulation, why it matters for abortion numbers nationwide, and the challenge of holding pro-life leaders accountable.